Try our Advanced Search for more refined results

March 28, 2014

IN RE: Testosterone Replacement Therapy Products Liability Litigation

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. June 29, 2018

    Actavis Reaches Tentative Deal To Exit Testosterone MDL

    Actavis Inc. is on its way to settling claims it failed to warn men about risks associated with its drug Androderm as part of multidistrict litigation over testosterone replacement therapy products, according to an order filed Friday.

10 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login